{
    "ticker": "MAPP",
    "name": "Mapp Biopharmaceuticals, Inc.",
    "description": "Mapp Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of innovative therapies for infectious diseases, with a specific emphasis on viral infections. Founded in 2003 and headquartered in San Diego, California, Mapp has established itself as a leader in the field of monoclonal antibody therapeutics. The company gained international recognition for its development of ZMapp, a treatment for Ebola virus disease, which was used during the 2014 Ebola outbreak. Mapp's proprietary technology platform allows for the rapid generation of monoclonal antibodies, which are engineered to target specific pathogens. This positions Mapp to respond to emerging infectious diseases effectively. In addition to its work on Ebola, Mapp is engaged in research and development for other viral diseases, including those caused by coronaviruses. The company's mission is to create safe and effective treatments that can save lives in the face of global health challenges, leveraging cutting-edge science and technology. Mapp Biopharmaceuticals collaborates with various governmental and non-governmental organizations to further its research and ensure its products reach those in need. With a commitment to scientific excellence and innovation, Mapp strives to lead the way in the biopharmaceutical industry, addressing critical health threats with urgency and precision.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2003",
    "website": "https://www.mappbio.com",
    "ceo": "H. Thomas McHugh",
    "social_media": {
        "twitter": "https://twitter.com/MappBio",
        "linkedin": "https://www.linkedin.com/company/mapp-biopharmaceuticals"
    },
    "investor_relations": "https://www.mappbio.com/investor-relations",
    "key_executives": [
        {
            "name": "H. Thomas McHugh",
            "position": "CEO"
        },
        {
            "name": "Robert W. E. M. W. W. Z. B. A. W. B. M. R. R. A. M.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ZMapp",
                "MP-12"
            ]
        }
    ],
    "seo": {
        "meta_title": "Mapp Biopharmaceuticals, Inc. | Innovative Infectious Disease Therapies",
        "meta_description": "Discover Mapp Biopharmaceuticals, Inc., a leader in the development of monoclonal antibodies for infectious diseases. Learn about their innovative therapies and scientific advancements.",
        "keywords": [
            "Mapp Biopharmaceuticals",
            "ZMapp",
            "Ebola Treatment",
            "Infectious Diseases",
            "Monoclonal Antibodies"
        ]
    },
    "faq": [
        {
            "question": "What is Mapp Biopharmaceuticals known for?",
            "answer": "Mapp Biopharmaceuticals is known for developing ZMapp, a treatment for Ebola virus disease."
        },
        {
            "question": "Who is the CEO of Mapp Biopharmaceuticals?",
            "answer": "H. Thomas McHugh is the CEO of Mapp Biopharmaceuticals, Inc."
        },
        {
            "question": "Where is Mapp Biopharmaceuticals headquartered?",
            "answer": "Mapp Biopharmaceuticals is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are the main products of Mapp Biopharmaceuticals?",
            "answer": "Mapp Biopharmaceuticals' main products include ZMapp and MP-12."
        },
        {
            "question": "When was Mapp Biopharmaceuticals founded?",
            "answer": "Mapp Biopharmaceuticals was founded in 2003."
        }
    ],
    "competitors": [
        "REGN",
        "AMGEN",
        "GILD",
        "JNJ"
    ],
    "related_stocks": [
        "AAPL",
        "AMZN",
        "MSFT",
        "GOOGL"
    ]
}